|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
National Institute on Drug Abuse (NIDA) University of Vermont |
| Information provided by: | National Institute on Drug Abuse (NIDA) |
| ClinicalTrials.gov Identifier: | NCT00000228 |
Purpose
The purpose of this study is to compare overall treatment outcome between behavioral versus standard treatment types.
| Condition | Intervention | Phase |
|
Opioid-Related Disorders |
Drug: Buprenorphine |
Phase II |
| ChemIDplus related topics: | Buprenorphine Buprenorphine hydrochloride |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Buprenorphine Detox With Two Types of Treatment. BBD I |
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Please contact site for information.
Contacts and Locations| United States, Vermont | |||||
| Treatment Research Center | |||||
| Burlington, Vermont, United States, 05401 | |||||
| National Institute on Drug Abuse (NIDA) |
| University of Vermont |
| Principal Investigator: | Warren Bickel, Ph.D. | University of Vermont |
More Information
| Study ID Numbers: | NIDA-06969-10, R01-06969-10 |
| First Received: | September 20, 1999 |
| Last Updated: | August 16, 2005 |
| ClinicalTrials.gov Identifier: | NCT00000228 |
| Health Authority: | United States: Federal Government |
|
|
|